Compare Adaptive Biotechnologies Corp (ADPT) vs Global X FTSE Southeast Asia ETF (ASEA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X FTSE Southeast Asia ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Global X FTSE Southeast Asia ETF trades at $20.16. Which is the better fit depends on your goals.
| ADPT | ASEA | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $20.65 |
52-Week Low | $10.24 | $16.25 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ASEA trades at $20.08, up 1.57% today, with technical indicators showing a bearish trend per moving averages while oscillators remain neutral. The stock faces resistance near $20 with support at $19. A dividend of $0.41 is scheduled for July 2026, but current financial ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook is cautious due to weak technical momentum and missing financial data. Risks include potential earnings volatility and market sentiment shifts. Investors should await updated SEC filings for valuation metrics before considering positions, as the bearish technical setup suggests near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →
